Literature DB >> 22041538

Pharmacokinetics of gefitinib and erlotinib.

Dominique Levêque.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22041538     DOI： 10.1016/S1470-2045(11)70306-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

Authors:  Alfredo Tartarone; Rosa Lerose; Chiara Lazzari; Vanesa Gregorc; Michele Aieta
Journal:  Med Oncol       Date:  2014-06-24       Impact factor: 3.064

2.  Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.

Authors:  Vanesa Gregorc; Chiara Lazzari; Niki Karachaliou; Rafael Rosell; Mariacarmela Santarpia
Journal:  Transl Lung Cancer Res       Date:  2018-04

3.  Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.

Authors:  Kyoung Min Cho; Bhumsuk Keam; Tae Min Kim; Se-Hoon Lee; Dong-Wan Kim; Dae Seog Heo
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.